Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6928280 | 0.98 | KDM4E (0.51) | KDM4EMAPTMEN1KMT2ATP53 | |
| Hydrochloric Acid SCHEMBL15954729 | 0.98 | KDM4E (0.51) | KDM4EMAPTMEN1KMT2ATP53 | |
| SCHEMBL161226 | 0.98 | KDM4E (0.50) | KDM4EMAPTMEN1KMT2ATP53 | |
| SCHEMBL3376199 | 0.94 | ADRA1A (0.49) | KDM4EMAPTMEN1KMT2ATP53 | |
| SCHEMBL6383642 | 0.90 | ADRA1A (0.51) | KDM4EMAPTMEN1KMT2ATP53 | |
| SCHEMBL161548 | 0.90 | ADRA1A (0.51) | KDM4EMAPTMEN1KMT2ATP53 | |
| Trifluoroacetic Acid SCHEMBL616099 | 0.89 | KDM4E (0.44) | KDM4EMAPTMEN1KMT2ATP53 | |
| Hydrochloric Acid SCHEMBL30170745 | 0.89 | ADRA1A (0.50) | KDM4EMAPTMEN1KMT2ATP53 | |
| SCHEMBL30646220 | 0.87 | ADRA1A (0.47) | KDM4EMAPTMEN1KMT2ATP53 | |
| SCHEMBL30100529 | 0.86 | KDM4E (0.58) | KDM4EMAPTMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024261504-A1 | BENZOFURAN-3-CARBOXYLIC ACID AMIDES AND BENZOFURAN-3- CARBONYL-BENZAMIDES, METHOD FOR THEIR PRODUCTION WITH HIGH SELECTIVITY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PÉCSI TUDOMÁNYEGYETEM (HU) | 2024-12-26 | — | — | WO | claimed |
| CN-118206854-B | High-strength plastic for automotive interior parts and preparation method thereof | 爱卓智能科技(常州)有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118206854-A | High-strength plastic for automotive interior parts and preparation method thereof | 爱卓智能科技(常州)有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-108103540-A | Tin alloy electric plating liquid | 永星化工(上海)有限公司 | 2018-06-01 | — | — | CN | claimed |
| CN-107001283-A | Flt3 receptor antagonists | 国家健康与医学研究院 | 2017-08-01 | — | — | CN | claimed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| CN-101490553-A | Methods of treating disease with PARP inhibitors | BIPAR SCIENCES INC (US) | 2009-07-22 | — | — | CN | claimed |
| EP-1611109-A4 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-06-24 | — | — | EP | claimed |
| EP-1807406-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | claimed |
| JP-2006522109-A | — | — | 2006-09-28 | — | — | JP | claimed |
| WO-2006047503-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA (BE) | 2006-05-04 | — | — | WO | claimed |
| EP-1611109-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-01-04 | — | — | EP | claimed |
| US-20050113566-A1 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-26 | — | — | US | claimed |
| WO-2004087680-A1 | NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| WO-2003047572-A1 | USE OF 1-PHENYL-OXAZOLIDINE-2-ONE COMPOUNDS AS PROTEASE M INHIBITORS | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | claimed |
| JP-5097805-A | — | — | None | — | — | JP | disclosed |
| WO-2024261504-A1 | BENZOFURAN-3-CARBOXYLIC ACID AMIDES AND BENZOFURAN-3- CARBONYL-BENZAMIDES, METHOD FOR THEIR PRODUCTION WITH HIGH SELECTIVITY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PÉCSI TUDOMÁNYEGYETEM (HU) | 2024-12-26 | — | — | WO | disclosed |
| US-4891297-A | STORAGE STABILITY, HIGH COLOR DENSITY | FUJI PHOTO FILM CO.,LTD. (JP) | 1990-01-02 | — | — | US | disclosed |
| EP-0323887-A2 | Heat-sensitive diazo recording materials | FUJI PHOTO FILM CO., LTD. (JP) | 1989-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | KDM4E 1855/4885MAPT 1941/4885MEN1 1111/4885 |
| US-20050113566-A1 | Inhibitors of C-FMS kinase | ALK, TYRO3, PDGFRB | KDM4E 2647/4885MAPT 4732/4885MEN1 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.